Adynovate

ApprovedBiologic

Takeda

Adynovate is one of 34 biologic programs targeting Severe Hemophilia a. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Severe Hemophilia aActive, not recruiting

Severe Hemophilia aApproved

Active, not recruiting

Competition

Competitive Landscape

59 competitors in Severe Hemophilia a

#DrugCompanyPhaseTrials

Hemlibra

Roche

Phase 3

3 2

Efanesoctocog Alfa

Sanofi

Phase 3

2 3

Rfviiifc

BBioverativ Therapeutics Inc.

Approved

3 4

Advate

Takeda

Phase 3

4 5

Rituxan

Roche

Phase 2

1 6

Qfitlia

GGenzyme, a Sanofi Company

Phase 3

4 7

Bypassing Agents

Roche

Phase 3

1 8

Recombinant Human Coagulation FVIII

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3

1 9

Recombinant Factor VIII

Bayer

Phase 3

4 10

Kogenate (BAY14-2222)

Bayer

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Post-ApprovalRecruiting

Severe Hemophilia a

NCT04690322

Clinical

Trials by Indication[1]

Severe Hemophilia a2 trials

A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A

Completed· Takeda logo

Takeda·Phase 3·NCT05707351·37 enrolled

POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT04690322·28 enrolled

Drug1 trial

ADYNOVATE Drug Use-Results Survey

Completed· Takeda logo

Takeda··NCT03169972·135 enrolled

Unspecified1 trial

Post Marketing Surveillance Study for ADYNOVATE in South Korea

Completed· Takeda logo

Takeda··NCT03824522·341 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Adynovate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Adynovate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Adynovate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Takeda company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: Takeda

Adynovate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Severe Hemophilia a2 trials

Drug1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News